<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">al.: </span>
   <span class="font30">factor </span>
   <span class="font21">hemophilia </span>
   <span class="font20">patients </span>
   <span class="font19">immune </span>
   <span class="font17">Recommendation </span>
   <span class="font17">VIII </span>
   <span class="font16">AAV </span>
   <span class="font16">clinical </span>
   <span class="font16">inhibitor </span>
   <span class="font16">risk </span>
   <span class="font16">therapy </span>
   <span class="font16">products </span>
   <span class="font16">FIX </span>
   <span class="font16">levels </span>
   <span class="font16">vector </span>
   <span class="font15">FVIII </span>
   <span class="font15">./blood--- </span>
   <span class="font15">expression </span>
   <span class="font15">gene </span>
   <span class="font15">subjects </span>
   <span class="font14">recombinant </span>
   <span class="font14">bleeding </span>
   <span class="font14">{border-style </span>
   <span class="font14">severe </span>
   <span class="font14">therapeutic </span>
   <span class="font13">protein </span>
   <span class="font13">px;} </span>
   <span class="font13">responses </span>
   <span class="font13">safety </span>
   <span class="font13">study </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">However, </span>
   <span class="font13">Med.;():–. </span>
   <span class="font13">NFTs </span>
   <span class="font13">inhibitors </span>
   <span class="font13">prophylaxis </span>
   <span class="font13">studies </span>
   <span class="font13">transgene </span>
   <span class="font13">development </span>
   <span class="font13">dose </span>
   <span class="font13">Factor </span>
   <span class="font13">Gene </span>
   <span class="font13">Haemost.;():–. </span>
   <span class="font13">Hemophilia </span>
   <span class="font13">disease </span>
   <span class="font13">haemophilia </span>
   <span class="font13">therapies </span>
   <span class="font13">trial </span>
   <span class="font12">AAV- </span>
   <span class="font12">EHL </span>
   <span class="font12">Engl </span>
   <span class="font12">increase </span>
   <span class="font12">liver </span>
   <span class="font12">use </span>
   <span class="font12">./NEJMoa </span>
   <span class="font12">./j.-...x </span>
   <span class="font12">emicizumab </span>
   <span class="font12">half-life </span>
   <span class="font12">increased </span>
   <span class="font12">treatment </span>
   <span class="font12">using </span>
   <span class="font12">virus </span>
   <span class="font12">activity </span>
   <span class="font12">capsid </span>
   <span class="font12">factors </span>
   <span class="font12">results </span>
   <span class="font12">thrombotic </span>
   <span class="font12">vg/kg </span>
   <span class="font12">./hae. </span>
   <span class="font12">cell </span>
   <span class="font12">data </span>
   <span class="font12">immunogenicity </span>
   <span class="font12">likely </span>
   <span class="font12">response </span>
   <span class="font12">strategies </span>
   <span class="font12">strategy </span>
   <span class="font12">treated </span>
   <span class="font11">ITI </span>
   <span class="font11">Thromb </span>
   <span class="font11">activated </span>
   <span class="font11">adeno-associated </span>
   <span class="font11">approximately </span>
   <span class="font11">coagulation </span>
   <span class="font11">cohort </span>
   <span class="font11">fusion </span>
   <span class="font11">human </span>
   <span class="font11">plasma-derived </span>
   <span class="font11">potential </span>
   <span class="font11">prevent </span>
   <span class="font11">receiving </span>
   <span class="font11">tolerance </span>
   <span class="font11">Ther.;():–. </span>
   <span class="font11">VWF </span>
   <span class="font11">antibody </span>
   <span class="font11">associated </span>
   <span class="font11">cellular </span>
   <span class="font11">complications </span>
   <span class="font11">decrease </span>
   <span class="font11">doses </span>
   <span class="font11">early </span>
   <span class="font11">efficacy </span>
   <span class="font11">exposure </span>
   <span class="font11">hemostatic </span>
   <span class="font11">higher </span>
   <span class="font11">new </span>
   <span class="font11">novel </span>
   <span class="font11">phase </span>
   <span class="font11">presented </span>
   <span class="font11">previously </span>
   <span class="font11">px; </span>
   <span class="font11">rFVIII </span>
   <span class="font11">trials </span>
   <span class="font11">venous </span>
   <span class="font11">{font-family </span>
   <span class="font11">International </span>
   <span class="font11">Recombinant </span>
   <span class="font11">SHL </span>
   <span class="font11">aPCC </span>
   <span class="font11">capsid-mediated </span>
   <span class="font11">current </span>
   <span class="font11">effect </span>
   <span class="font11">font-size </span>
   <span class="font11">hemostasis </span>
   <span class="font11">immunosuppression </span>
   <span class="font11">long-term </span>
   <span class="font11">pdFVIII </span>
   <span class="font11">preclinical </span>
   <span class="font11">product </span>
   <span class="font11">recent </span>
   <span class="font11">replacement </span>
   <span class="font11">./jth. </span>
   <span class="font11">ALT </span>
   <span class="font11">Paper </span>
   <span class="font11">Society </span>
   <span class="font11">Thrombosis </span>
   <span class="font11">Thus, </span>
   <span class="font11">at: </span>
   <span class="font11">available </span>
   <span class="font11">bypassing </span>
   <span class="font11">codon </span>
   <span class="font11">demonstrated </span>
   <span class="font11">dogs </span>
   <span class="font11">double; </span>
   <span class="font11">effective </span>
   <span class="font11">insect </span>
   <span class="font11">large </span>
   <span class="font11">line </span>
   <span class="font11">natural </span>
   <span class="font11">optimization </span>
   <span class="font11">patients, </span>
   <span class="font11">prophylactic </span>
   <span class="font11">required </span>
   <span class="font11">steroids </span>
   <span class="font11">studies. </span>
   <span class="font11">suggest </span>
   <span class="font11">underlying </span>
   <span class="font11">used </span>
   <span class="font11">vectors </span>
   <span class="font11">viral </span>
   <span class="font11">Berlin, </span>
   <span class="font11">Clinical </span>
   <span class="font11">Congress </span>
   <span class="font11">FIX-Padua </span>
   <span class="font11">Fusion </span>
   <span class="font11">Haemostasis; </span>
   <span class="font11">Immune </span>
   <span class="font11">Inhibitors </span>
   <span class="font11">SIPPET </span>
   <span class="font11">Suppl </span>
   <span class="font11">benefits </span>
   <span class="font11">biological </span>
   <span class="font11">bispecific </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">challenging </span>
   <span class="font11">competing </span>
   <span class="font11">complex </span>
   <span class="font11">complication </span>
   <span class="font11">currently </span>
   <span class="font11">date, </span>
   <span class="font11">developed </span>
   <span class="font11">dose-dependent </span>
   <span class="font11">efficacious </span>
   <span class="font11">emerging </span>
   <span class="font11">enzymes </span>
   <span class="font11">formation </span>
   <span class="font11">generation </span>
   <span class="font11">high </span>
   <span class="font11">history </span>
   <span class="font11">improved </span>
   <span class="font11">include </span>
   <span class="font11">induction </span>
   <span class="font11">infusion </span>
   <span class="font11">management </span>
   <span class="font11">normal </span>
   <span class="font11">ongoing </span>
   <span class="font11">population </span>
   <span class="font11">products, </span>
   <span class="font11">profile </span>
   <span class="font11">provide </span>
   <span class="font11">rFVIII–Fc </span>
   <span class="font11">randomized </span>
   <span class="font11">rate </span>
   <span class="font11">regarding </span>
   <span class="font11">reported </span>
   <span class="font11">require </span>
   <span class="font11">responses. </span>
   <span class="font11">solid; </span>
   <span class="font11">sustained </span>
   <span class="font11">therapeutics </span>
   <span class="font11">thrombosis </span>
   <span class="font11">weeks </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">./S-()- </span>
   <span class="font10">A.Blood.;():–. </span>
   <span class="font10">A.N </span>
   <span class="font10">EHL–rFVIII </span>
   <span class="font10">Emicizumab </span>
   <span class="font10">FIXa </span>
   <span class="font10">FXa </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Inhibitor </span>
   <span class="font10">NFT </span>
   <span class="font10">Therapy </span>
   <span class="font10">University </span>
   <span class="font10">Willebrand </span>
   <span class="font10">Yes </span>
   <span class="font10">ability </span>
   <span class="font10">access </span>
   <span class="font10">additional </span>
   <span class="font10">agents </span>
   <span class="font10">and/or </span>
   <span class="font10">animal </span>
   <span class="font10">attractive </span>
   <span class="font10">based </span>
   <span class="font10">best </span>
   <span class="font10">better </span>
   <span class="font10">biochemical </span>
   <span class="font10">bold </span>
   <span class="font10">breakthrough </span>
   <span class="font10">care </span>
   <span class="font10">clinicians </span>
   <span class="font10">combined </span>
   <span class="font10">concern </span>
   <span class="font10">concerns </span>
   <span class="font10">cost </span>
   <span class="font10">courier; </span>
   <span class="font10">decreased </span>
   <span class="font10">deficiency </span>
   <span class="font10">delivery </span>
   <span class="font10">disclosed. </span>
   <span class="font10">distinct </span>
   <span class="font10">does </span>
   <span class="font10">earlier </span>
   <span class="font10">em; </span>
   <span class="font10">enhance </span>
   <span class="font10">especially </span>
   <span class="font10">experienced </span>
   <span class="font10">extended </span>
   <span class="font10">following </span>
   <span class="font10">frequency </span>
   <span class="font10">future </span>
   <span class="font10">hemophilia: </span>
   <span class="font10">high-dose </span>
   <span class="font10">inhibitors. </span>
   <span class="font10">innate </span>
   <span class="font10">interests </span>
   <span class="font10">joint </span>
   <span class="font10">level </span>
   <span class="font10">levels, </span>
   <span class="font10">loss </span>
   <span class="font10">mammalian </span>
   <span class="font10">models </span>
   <span class="font10">needed </span>
   <span class="font10">observed </span>
   <span class="font10">occurred </span>
   <span class="font10">order </span>
   <span class="font10">pharmacokinetic </span>
   <span class="font10">plasma </span>
   <span class="font10">possibility </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">remains </span>
   <span class="font10">replacement. </span>
   <span class="font10">represented </span>
   <span class="font10">resulted </span>
   <span class="font10">role </span>
   <span class="font10">safe </span>
   <span class="font10">standard </span>
   <span class="font10">stratification </span>
   <span class="font10">such, </span>
   <span class="font10">technologies </span>
   <span class="font10">therapy, </span>
   <span class="font10">thrombin </span>
   <span class="font10">tissue </span>
   <span class="font10">treat </span>
   <span class="font10">trials, </span>
   <span class="font10">untreated </span>
   <span class="font10">von </span>
  </p>
 </body>
</html>
